» Articles » PMID: 21793043

Stem Cell Activation in Adults Can Reverse Detrimental Changes in Body Composition to Reduce Fat and Increase Lean Mass in Both Sexes

Overview
Journal J Cell Biochem
Date 2011 Jul 28
PMID 21793043
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Detrimental changes in body composition are often associated with declining levels of testosterone. Here, we evaluated the notion that multipotent mesenchymal stem cells, that give rise to both fat and muscle tissue, can play a significant role to alter existing body composition in the adult. Transgenic mice with targeted androgen receptor (AR) overexpression in stem cells were employed. Wild-type littermate and AR-transgenic male and female mice were gonadectomized and left untreated for 2 months. After the hypogonadal period, mice were then treated with 5α-dihydrotestosterone (DHT) for 6 weeks. After orchidectomy (ORX), wild-type males have reduced lean mass and increased fat mass compared to shams. DHT treatment was beneficial to partially restore body composition. In wild-type females, ovariectomy (OVX) produced a similar change but there was no improvement with DHT. In targeted AR transgenic mice, DHT treatment increased lean and reduced fat mass to sham levels. In contrast to wild-type females, DHT treatment in female transgenic mice significantly ameliorated the increased fat and decreased lean mass changes that result after OVX. Our results show that DHT administration reduces fat mass and increases lean mass in wild-type males but not females, indicating that wild-type females are not as sensitive to androgen treatment. Because both male and female transgenic mice are more responsive than wild-type, results suggest that body composition remains linked to stem cell fate in the adult and that targeted androgen signaling in stem cells can play a significant role to reverse detrimental changes in body composition in both sexes.

Citing Articles

The role of the androgen receptor in the pathogenesis of obesity and its utility as a target for obesity treatments.

Venkatesh V, Grossmann M, Zajac J, Davey R Obes Rev. 2022; 23(6):e13429.

PMID: 35083843 PMC: 9286619. DOI: 10.1111/obr.13429.


Androgen prevents hypogonadal bone loss via inhibition of resorption mediated by mature osteoblasts/osteocytes.

Wiren K, Zhang X, Olson D, Turner R, Iwaniec U Bone. 2012; 51(5):835-46.

PMID: 22910580 PMC: 3455127. DOI: 10.1016/j.bone.2012.08.111.

References
1.
Hatzistergos K, Quevedo H, Oskouei B, Hu Q, Feigenbaum G, Margitich I . Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res. 2010; 107(7):913-22. PMC: 3408082. DOI: 10.1161/CIRCRESAHA.110.222703. View

2.
Nantermet P, Masarachia P, Gentile M, Pennypacker B, Xu J, Holder D . Androgenic induction of growth and differentiation in the rodent uterus involves the modulation of estrogen-regulated genetic pathways. Endocrinology. 2004; 146(2):564-78. DOI: 10.1210/en.2004-1132. View

3.
Gupta V, Bhasin S, Guo W, Singh R, Miki R, Chauhan P . Effects of dihydrotestosterone on differentiation and proliferation of human mesenchymal stem cells and preadipocytes. Mol Cell Endocrinol. 2008; 296(1-2):32-40. PMC: 2873614. DOI: 10.1016/j.mce.2008.08.019. View

4.
Williams A, Trachtenberg B, Velazquez D, McNiece I, Altman P, Rouy D . Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ Res. 2011; 108(7):792-6. PMC: 3390160. DOI: 10.1161/CIRCRESAHA.111.242610. View

5.
Grossmann M . Low testosterone in men with type 2 diabetes: significance and treatment. J Clin Endocrinol Metab. 2011; 96(8):2341-53. DOI: 10.1210/jc.2011-0118. View